HEMOSTASIA E PAREDE VASCULAR: DOENÇAS DA COAGULAÇÃO E FIBRINÓLISE
A SIMULATION STUDY TO PROVIDE GUIDANCE FOR INDIVIDUALS TRANSITIONING FROM EMICIZUMAB TO VALOCTOCOGENE ROXAPARVOVEC
W Kuwabaraa, D Osmondb, J Henshawb, S Agarwalb, V Newmanb, C Hermansc, W Miesbachd, S Pipee, RS Jrf, F Peyvandig,h
a BioMarin Farmacêutica do Brasil Ltda., São Paulo, Brazil
b BioMarin Pharmaceutical Inc., Novato, United States
c Division of Adult Haematology, St-Luc University Hospital, Brussels, Belgium
d Medical Clinic 2, University Hospital, Frankfurt, Germany
e Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, United States
f Hemostasis and Thrombosis at Children's Healthcare of Atlanta, Emory University, Atlanta, United States
g Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fondazione Luigi Villa, Milan, Italy
h Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy
Read
1115
Timeswas read the article
419
Total PDF
696
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 9 | 7 | 1 | 8 |
| 2025 8 | 32 | 17 | 49 |
| 2025 7 | 41 | 22 | 63 |
| 2025 6 | 33 | 15 | 48 |
| 2025 5 | 39 | 8 | 47 |
| 2025 4 | 37 | 11 | 48 |
| 2025 3 | 50 | 8 | 58 |
| 2025 2 | 36 | 19 | 55 |
| 2025 1 | 28 | 21 | 49 |
| 2024 12 | 19 | 20 | 39 |
| 2024 11 | 23 | 21 | 44 |
| 2024 10 | 28 | 23 | 51 |
| 2024 9 | 30 | 19 | 49 |
| 2024 8 | 34 | 14 | 48 |
| 2024 7 | 30 | 25 | 55 |
| 2024 6 | 31 | 23 | 54 |
| 2024 5 | 36 | 30 | 66 |
| 2024 4 | 27 | 13 | 40 |
| 2024 3 | 34 | 24 | 58 |
| 2024 2 | 16 | 22 | 38 |
| 2024 1 | 57 | 14 | 71 |
| 2023 12 | 16 | 24 | 40 |
| 2023 11 | 10 | 13 | 23 |
| 2023 10 | 2 | 12 | 14 |
Show all
